The Scotts Miracle-Gro Company
SMG
$63.82
+3.84%
The Scotts Miracle-Gro Company is the largest purveyor of home lawn and gardening products in the United States, operating within the Agricultural Inputs industry. Its business is built on a portfolio of well-recognized consumer brands, including Scotts, Miracle-Gro, Roundup, Ortho, and Tomcat, which provide a broad range of lawncare and gardening products such as grass seed, fertilizer, and pest control solutions. The current investor narrative centers on the company's ongoing financial recovery and operational turnaround, following a period of significant challenges in its Hawthorne segment and broader industry headwinds. Recent attention is focused on the company's efforts to reduce its substantial debt load, improve free cash flow generation, and navigate the seasonal and cyclical nature of its consumer business, with the stock's performance reflecting debates about the sustainability of its margin improvement and the pace of its balance sheet repair.…
SMG
The Scotts Miracle-Gro Company
$63.82
Investment Opinion: Should I buy SMG Today?
Rating & Thesis: The stock is rated a Hold. The core thesis is that SMG is a high-risk, speculative turnaround story where the potential for operational recovery and debt reduction is counterbalanced by severe balance sheet distress and inconsistent profitability, making the risk/reward profile unattractive for all but the most risk-tolerant investors. The mixed analyst sentiment (a recent downgrade to Neutral by JP Morgan alongside maintained Buy/Overweight ratings from others) reflects this uncertainty.
Supporting Evidence: The valuation appears low with a PS ratio of 0.96, but this is justified by fundamental risks including a negative ROE of -40.62% and a quarterly revenue decline of 14.97% YoY. While TTM free cash flow of $358.1M is a strong positive, it is being deployed to repair a balance sheet with negative equity. The forward P/E of 13.22 implies a return to profitability, but this is not yet evidenced in recent quarterly results. The stock trades at 88% of its 52-week high, suggesting limited near-term upside without a flawless execution of the turnaround plan.
Risks & Conditions: The two biggest risks are a failure to sustain free cash flow generation, jeopardizing debt service, and a re-acceleration of revenue declines. This Hold rating would upgrade to a Buy if the company demonstrates two consecutive quarters of positive net income while reducing absolute debt, or if the stock price falls below $50, offering a significantly larger margin of safety. It would downgrade to a Sell if quarterly free cash flow turns negative or if the Debt-to-Equity ratio deteriorates further. Relative to its own distressed history, the stock is fairly valued given the substantial execution risk ahead.
Sign up to view all
SMG 12-Month Price Forecast
The outlook for SMG is bifurcated between its operational cash-generating ability and its dire balance sheet position. The base case (50% probability) of a grinding, volatile recovery is most likely, as the company uses its strong brands to generate cash but remains constrained by its leverage. The bull case depends on flawless execution and multiple expansion, while the bear case is a very real possibility given the financial leverage. The stance would upgrade to bullish on evidence of sustained quarterly profitability and material debt reduction. It would turn bearish if free cash flow meaningfully declines or if revenue deterioration accelerates beyond the recent -14.97% YoY drop.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Scotts Miracle-Gro Company's 12-month outlook, with a consensus price target around $82.97 and implied upside of +30.0% versus the current price.
Average Target
$82.97
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$51 - $83
Analyst target range
Analyst coverage for SMG is limited, with only 3 analysts providing estimates, which is indicative of a mid-cap stock with constrained institutional interest that can lead to higher volatility and less efficient price discovery. The available data shows consensus estimates for EPS and revenue but does not provide a consensus price target, buy/hold/sell distribution, or a target price range. This lack of explicit target data means the typical metrics for gauging analyst sentiment—such as implied upside and consensus rating—cannot be calculated from the provided dataset. Given the insufficient explicit target data, the implications of limited coverage must be emphasized. The stock's investment case is less shaped by a broad Wall Street narrative and more by company-specific execution on its debt reduction and seasonal execution. The recent institutional rating actions show a mixed but stabilizing picture: JP Morgan downgraded to Neutral from Overweight in March 2026, while Stifel maintained a Buy and Wells Fargo maintained an Overweight rating earlier in the year. The absence of a wide target price range from a large analyst pool increases the stock's susceptibility to sharp moves on company-specific news, as fewer professional opinions anchor market expectations.
Bulls vs Bears: SMG Investment Factors
The evidence presents a classic high-risk, high-potential-reward turnaround story. The bull case is anchored by strong free cash flow generation ($358.1M TTM) and significant sequential margin improvement (Q1 gross margin of 25.03% vs. -7.11% in Q4 FY2024), suggesting operational recovery is underway. The bear case is dominated by a severely distressed balance sheet (D/E of -6.66) and persistent quarterly losses, raising solvency concerns. Currently, the bearish evidence carries more weight due to the fundamental financial risk and recent revenue decline. The single most important tension in the investment debate is whether the company's robust free cash flow can sustainably outpace its debt burden and fund a complete operational turnaround before a macroeconomic or sector-specific downturn pressures its core consumer business.
Bullish
- Strong Free Cash Flow Generation: The company has generated substantial TTM free cash flow of $358.1 million, providing crucial liquidity for debt reduction and operational flexibility. This is a key positive sign in a turnaround scenario, demonstrating the underlying cash-generative power of its core consumer brands despite reported net losses.
- Significant Margin Recovery in Q1: Q1 FY2026 gross margin improved to 25.03%, a major sequential recovery from the disastrous -7.11% in Q4 FY2024. This indicates the operational turnaround is gaining traction, with underlying product profitability moving back towards the TTM gross margin level of 30.59%.
- Valuation at Historical Lows: Trading at a Price-to-Sales (PS) ratio of 0.96, the stock is near the low end of its historical range, pricing in significant skepticism. This provides a potential margin of safety for a deep-value turnaround play if the company's recovery continues.
- Technical Support After Pullback: The stock has pulled back 8.09% in the past month from its 52-week high of $72.35, trading at ~$63.88. This consolidates prior gains and may offer a more attractive entry point, with the 52-week low of $45.61 providing a clear downside anchor.
Bearish
- Severely Leveraged Balance Sheet: The company's financial health is precarious, with a deeply negative Debt-to-Equity ratio of -6.66 and a negative Return on Equity (ROE) of -40.62%. This indicates accumulated losses have eroded the equity base, making the company highly dependent on continued positive cash flow to service obligations.
- Persistent Quarterly Losses: The company reported a Q1 FY2026 net loss of $125 million on revenue of $354.4M, continuing a pattern of seasonal losses. While the full-year TTM net margin is positive at 4.25%, the path to consistent quarterly profitability remains uncertain.
- Revenue Decline and Demand Pressure: Q1 FY2026 revenue declined 14.97% year-over-year to $354.4M, signaling ongoing challenges in consumer demand or retailer inventory management. This casts doubt on the near-term growth trajectory of the core business.
- High Volatility and Market Sensitivity: With a beta of 1.924, the stock is approximately 92% more volatile than the broader market. This elevated beta increases risk, as the stock will amplify any market downturn, as seen in its recent 8.09% monthly decline versus the S&P 500's -4.28%.
SMG Technical Analysis
The stock is in a sustained recovery trend, having gained 10.21% over the past year, but it has recently experienced a significant pullback from its highs. As of the latest data, the stock is trading at approximately $63.88, which places it at about 88% of its 52-week high of $72.35 and well above its 52-week low of $45.61, indicating it is in the upper portion of its annual range but has retreated from peak momentum levels. This positioning suggests the stock is consolidating after a strong run, with the recent pullback potentially offering a more attractive entry point for investors who believe in the ongoing turnaround story, though it remains vulnerable to further selling pressure if the broader recovery narrative falters. Recent momentum has turned sharply negative, with the stock declining 8.09% over the past month, which starkly contrasts with its positive 7.49% gain over the past three months. This divergence signals a significant short-term deceleration and potential trend reversal, likely driven by profit-taking after the stock's rally to its 52-week high in February and broader market volatility. The stock's 1-month relative strength of -3.81% versus the S&P 500's -4.28% decline shows it has slightly underperformed the market during this recent downturn, indicating it is not acting as a defensive haven but is instead being sold alongside the broader market. Key technical support is anchored at the 52-week low of $45.61, while immediate resistance sits at the recent 52-week high of $72.35. A decisive breakout above $72.35 would signal a resumption of the primary uptrend and potentially open the path to new highs, whereas a breakdown below key support levels around $60 could trigger a deeper correction toward the $50-$55 zone. The stock exhibits high volatility, with a beta of 1.924, meaning it is approximately 92% more volatile than the broader market; this elevated beta underscores the stock's sensitivity to market swings and sector-specific news, necessitating larger position-sizing buffers for risk management.
Beta
1.92
1.92x market volatility
Max Drawdown
-25.3%
Largest decline past year
52-Week Range
$46-$72
Price range past year
Annual Return
+32.4%
Cumulative gain past year
| Period | SMG Return | S&P 500 |
|---|---|---|
| 1m | -0.8% | -0.3% |
| 3m | +5.0% | -2.0% |
| 6m | +15.0% | +3.5% |
| 1y | +32.4% | +36.2% |
| ytd | +7.4% | -0.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SMG Fundamental Analysis
Revenue growth is highly seasonal and currently showing signs of pressure, with the most recent Q1 FY2026 revenue of $354.4 million representing a 14.97% year-over-year decline. This follows a volatile pattern: Q4 FY2025 revenue was $387.4 million, Q3 was a strong $1.188 billion, and Q2 was $1.421 billion, highlighting the company's peak selling seasons in Q2 and Q3. The U.S. Consumer segment, which generated $328.5 million in the latest quarter, remains the dominant driver, but the overall YoY decline indicates ongoing challenges in consumer demand or retailer inventory management, which tempers the near-term growth trajectory. Profitability remains challenged on a quarterly basis due to seasonality, with the latest Q1 reporting a net loss of $125 million and a gross margin of 25.03%. However, the full-year picture is more nuanced: the trailing twelve-month free cash flow is a robust $358.1 million, and the company's net margin on a TTM basis is positive at 4.25%. The Q1 gross margin of 25.03% shows a sequential improvement from the disastrous -7.11% gross margin in Q4 FY2024, indicating a significant recovery in underlying product profitability, though it remains below the 30.59% gross margin indicated in the valuation data, suggesting there is further room for operational improvement. The balance sheet carries significant financial risk, evidenced by a deeply negative debt-to-equity ratio of -6.66 and a negative Return on Equity (ROE) of -40.62%, both symptomatic of accumulated losses that have eroded the equity base. Positively, the company generated substantial TTM free cash flow of $358.1 million, which provides crucial liquidity for debt repayment. The current ratio of 1.27 indicates adequate short-term liquidity, but the highly leveraged capital structure, with shareholders' equity in negative territory, means the company's financial health is critically dependent on sustained positive cash flow generation to service its obligations and avoid further balance sheet distress.
Quarterly Revenue
$354400000.0B
2025-12
Revenue YoY Growth
-0.14%
YoY Comparison
Gross Margin
+0.25%
Latest Quarter
Free Cash Flow
$358099999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SMG Overvalued?
Given the company's inconsistent profitability with a recent quarterly net loss, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 0.96, which is notably low and suggests the market is assigning a discounted multiple to its revenue base, likely due to concerns over margins and leverage. A forward PE ratio of 13.22 is also available, but its utility is limited without a clear, sustained path to consistent net income; the gap between the negative trailing PE and positive forward PE implies analysts expect a return to profitability, but the high uncertainty renders the PS ratio a more stable measure for cross-sectional comparison. Compared to industry averages, which are not provided in the dataset, a definitive sector premium or discount cannot be quantified. However, a PS ratio below 1.0 is generally considered value-oriented, especially for a market leader. The valuation must be assessed in the context of the company's weak profitability metrics (negative ROE, compressed margins) and high financial leverage (negative D/E). Any potential discount is likely justified by these substantial fundamental risks, and a premium would only be warranted if the market had high conviction in a rapid and successful debt reduction and margin expansion story, which current metrics do not yet support. Historically, the stock's own valuation tells a story of distress and recovery. The current PS ratio of 0.96 is near the lower end of its historical range observed in the provided data, which has seen extreme swings (e.g., 9.46 in Q1 2026, 11.90 in Q4 2024). Trading near historical lows suggests the market is pricing in significant skepticism, potentially viewing the stock as a deep-value turnaround play if operational improvements continue. However, it could also reflect a justified pricing of persistent structural issues, meaning the low multiple may not necessarily signal an obvious buying opportunity without fundamental confirmation.
PE
22.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -45x~20x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary risk is the company's highly leveraged capital structure, with a Debt-to-Equity ratio of -6.66 and negative shareholder equity, indicating it is technically insolvent on a book value basis. This is compounded by persistent quarterly operating losses, as evidenced by the Q1 FY2026 net loss of $125 million, which strains liquidity despite strong TTM free cash flow of $358.1 million. Revenue concentration in the seasonal U.S. Consumer segment and a recent 14.97% YoY revenue decline in Q1 further expose the company to demand volatility and inventory corrections at major retailers.
Market & Competitive Risks: The stock trades with high market sensitivity, evidenced by its beta of 1.924, making it vulnerable to broader market sell-offs and sector rotation out of cyclical consumer staples. Valuation compression is a significant risk; while the PS ratio of 0.96 appears cheap, it could contract further if margin recovery stalls or debt reduction slows. Competitive risks are inherent in a mature industry, and the company's need to invest in brand marketing while simultaneously deleveraging creates a challenging capital allocation tension. The lack of a broad analyst consensus (only 3 covering analysts) exacerbates price volatility on company-specific news.
Worst-Case Scenario: The worst-case scenario involves a recessionary downturn in consumer spending coinciding with a failure to maintain gross margin improvements. This would lead to a double-hit of declining revenue and renewed margin pressure, causing free cash flow to turn negative. With a highly leveraged balance sheet, the company could face a liquidity crisis, forcing dilutive equity issuance or distressed debt restructuring. In this adverse scenario, the stock could realistically re-test its 52-week low of $45.61, representing a downside of approximately -29% from the current price of ~$63.88. A drawdown to this level would be consistent with its historical max drawdown of -25.26%.
FAQ
The key risks, in order of severity, are: 1) Financial Risk: The company's balance sheet is technically insolvent with a Debt-to-Equity ratio of -6.66, making it vulnerable to any cash flow interruption. 2) Operational Risk: The business is highly seasonal and recently reported a 14.97% YoY revenue decline in Q1 FY2026, indicating demand weakness. 3) Market Risk: The stock has a beta of 1.924, meaning it is 92% more volatile than the market, amplifying losses during downturns. 4) Execution Risk: The turnaround depends on sustained margin improvement and debt reduction; any misstep could lead to a liquidity crisis.
The 12-month forecast presents three scenarios with associated probabilities. The Base Case (50% probability) sees the stock trading between $60 and $72, reflecting a volatile, grinding recovery with gradual debt reduction. The Bull Case (25% probability) projects a range of $72 to $85, driven by successful turnaround execution, consistent profitability, and multiple expansion. The Bear Case (25% probability) forecasts a decline to between $45 and $55, triggered by a stall in operational recovery and renewed balance sheet concerns. The base case is most likely, assuming the company continues its uneven progress without a major catalyst or setback.
SMG appears fairly valued relative to its current risk profile. The primary valuation metric, the Price-to-Sales (PS) ratio of 0.96, is low and suggests the market is not assigning a premium to its revenue, which is appropriate given its financial condition. A forward P/E of 13.22 implies analysts expect a return to profitability, but this is not yet reflected in quarterly results. Compared to its own history, the stock trades near the lower end of its range, but this discount is justified by its negative shareholder equity and high leverage. The valuation implies the market expects a prolonged and uncertain recovery, pricing in a significant probability of failure.
SMG is a high-risk, speculative investment and is not a good buy for most investors. It is suitable only for aggressive, risk-tolerant investors comfortable with turnaround situations. The stock offers a potential margin of safety with a PS ratio of 0.96 and strong TTM free cash flow of $358.1M, but these are offset by severe balance sheet distress (D/E of -6.66) and inconsistent profitability. The 29% potential downside to its 52-week low of $45.61 represents a significant risk. It could be a good buy for a specialized deep-value portfolio if purchased on a significant pullback and with the conviction that the operational recovery will continue unabated.
SMG is unsuitable for short-term trading due to its high volatility (beta 1.924) and lack of near-term positive catalysts. It is theoretically a long-term investment, but only for investors with a 3-5 year horizon who are betting on a complete financial turnaround. The dividend yield of 4.7% is not a reliable source of income as the payout ratio exceeds 100%. Given the company's stage—a financially distressed entity in recovery—the investment thesis requires time for debt reduction and margin stabilization to play out. A minimum holding period of 2-3 years is suggested to assess whether the turnaround is succeeding.